Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis (2014) 3.69

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS (2014) 2.04

HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94

Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis (2013) 1.92

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV (2015) 1.76

Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med (2015) 1.65

Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One (2013) 1.46

Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clin Infect Dis (2015) 1.45

When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med (2013) 1.30

Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013. Global Health (2014) 1.26

Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr (2013) 1.24

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc (2014) 1.23

Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials (2012) 1.11

Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther (2015) 1.08

Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01

Should we treat acute HIV infection? Curr HIV/AIDS Rep (2012) 1.00

High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/μL under routine program conditions in Uganda. Clin Infect Dis (2013) 0.98

When to start antiretroviral therapy: as soon as possible. BMC Med (2013) 0.95

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS (2015) 0.87

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med (2015) 0.86

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 0.85

Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. Antiviral Res (2013) 0.85

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal? Clin Infect Dis (2012) 0.84

The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother (2013) 0.79

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. Pediatrics (2014) 0.79

Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy. Stat Med (2016) 0.79

Closing the Gap in Antiretroviral Initiation and Viral Suppression: Time Trends and Racial Disparities. J Acquir Immune Defic Syndr (2016) 0.78

Modeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimes. PLoS One (2012) 0.77

Comparison of HIV outcomes for patients linked at hospital versus community-based clinics. AIDS Patient Care STDS (2015) 0.75

HAART for HIV-1 infection: zeroing in on when to start: comment on "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters". Arch Intern Med (2011) 0.75

Associations of HIV testing and late diagnosis at a Japanese university hospital. Clinics (Sao Paulo) (2016) 0.75

Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75

Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. J Acquir Immune Defic Syndr (2016) 0.75

Can we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA Panel. J Int AIDS Soc (2014) 0.75

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26

Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54

CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01

Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35

Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25

Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38

Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84

When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol (2001) 2.84

Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis (2009) 2.26

Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med (2004) 2.04

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88

Early antiretroviral therapy: the role of cohorts. Curr Opin HIV AIDS (2009) 0.96